MTD Group Acquires Ypsomed’s Pen Needles, Blood Glucose Monitoring Systems

Pharmaceutical Executive August 5, 2024
Don Tracy, Associate Editor

The acquisition of Ypsomed’s pen needles and blood glucose monitoring system is expected to increase MTD’s production capacity to over 2.5 billion units.

MTD Group has completed its acquisition of Ypsomed’s Pen Needles and Blood Glucose Monitoring Systems businesses. According to the company, the acquisition is poised to increase MTD’s production capacity to over 2.5 billion units. The company also stated that by implementing Ypsomed’s operations into its European network, its diabetes and obesity care portfolio will be enhanced as a result. Moving forward, MTD plans on investing in the development of production facilities in Europe, aiming to boost capacity and quality while enhancing its ESG credentials.¹

“The completion of this acquisition marks a transformative moment for MTD Group. By...

Today's Sponsors

Today's Sponsor